24 June 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Appointment of Independent Non-Executive Director

Seasoned biotech and capital markets leader joins the Board

Coiled Therapeutics (AIM: COIL) (OTCQB: COTFX), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces the appointment of Craig A. Tooman as an Independent Non-Executive Director with effect from 25 June 2026.

Mr Tooman most recently served as President, Chief Executive Officer and Board Director of Silence Therapeutics, the NASDAQ-listed siRNA company and brings over 30 years of international pharmaceutical and biotechnology leadership experience spanning clinical, operational, financial, M&A and capital markets disciplines, including more than 20 years as a public company CEO and CFO. In these executive roles and as a Board member, he directly participated in the raising of nearly US$9 billion in capital.

At Silence Therapeutics, he helped transform the business from an early-stage UK research enterprise mainly trading on AIM into a well-financed NASDAQ listed global development company with multiple assets in later-stage clinical trials, including a first-in-class treatment for polycythemia vera.

Throughout his career, he has played leading roles building, financing and realising value in life-science companies, participating in the execution of numerous strategic transactions across the biotechnology sector. As President, CEO and Board Director of Aratana Therapeutics, he negotiated the company's US$250 million merger with Elanco following Aratana Therapeutics' Bloomberg "IPO of the Year" award in 2013 and a record-setting three US regulatory approvals in a single year. As CFO of Enzon Pharmaceuticals, he coordinated the sale of its specialty pharmaceutical business to Sigma Tau for over US$300 million, and at ILEX Oncology he led the US$1.1 billion acquisition by Genzyme Corporation, including its integration. Earlier in his career, he held senior strategic and investor relations roles at Pharmacia, Pharmacia & Upjohn and The Upjohn Company in the US, Europe and Japan.

Mr Tooman also brings extensive board experience, having served on the Supervisory Board of CureVac N.V. from 2019 until its acquisition by BioNTech in 2025, where he chaired both the Compensation and Nomination/Governance Committees, and on the boards of Aratana Therapeutics, Verté Therapeutics, Ondine Biomedical, Insite Vision and Xanodyne Pharmaceuticals, chairing the Audit Committees of four of these companies. His deep oncology heritage, including building the most valuable oncology business in Texas (ILEX Oncology) during the period 2002-2005, for which he was awarded the first Entrepreneur in Residence (EIR) designation by the Cancer Prevention and Research Institute of Texas (CPRIT), aligns directly with Coiled Therapeutics' precision oncology focus and its lead candidate, AO-252.

Commenting on the appointment, Sotirios Stergiopoulos, Chairman of Coiled Therapeutics, said:

"We are delighted to welcome Craig to the Board of Coiled Therapeutics. His exceptional public company track record, deep oncology expertise and proven ability to finance and scale clinical-stage companies will be of considerable value as we advance our lead asset, AO-252, through the clinic. His experience building publicly listed biotechnology companies and engaging with global investors will further strengthen the Board as we execute our clinical and corporate strategy. Craig's international capital markets experience will be invaluable as the Company progresses its development plans and broadens its investor base."

Craig Tooman, Non-Executive Director, added:

"I am excited to be joining Coiled Therapeutics at such a promising stage in the Company's development. The early clinical signals for AO-252 are highly encouraging, and I am impressed by the innovative science behind the Company's first-in-class, brain-penetrant TACC3 inhibitor and the breadth of opportunity it presents in hard-to-treat solid tumours. I look forward to working with the Board to help drive this promising technology through the next stages of development and to support the Company's strategic objectives."

The following disclosures are made pursuant to Schedule 2(g) of the AIM Rules for Companies:

Craig Allen Tooman, aged 60, currently holds or has held the following directorships or partnerships in the past five years:

Mr Tooman currently holds no ordinary shares in the Company. In conjunction with his appointment, Mr Tooman has been granted options over 4,000,000 ordinary shares in the Company (the "Options"), of which 2,000,000 Options will vest after 6 months, with the remaining 2,000,000 vesting after 12 months. The Options have an exercise price of 10 pence each. There are no further disclosures required in accordance with AIM Rule 17 or Schedule 2(g) of the AIM Rules for Companies.

-Ends-

Enquiries:

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884).  Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.   The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.

The asset is currently being evaluated in an ongoing Phase I open-label dose-escalation study. The Company plans to initiate dose-expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.